Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Renee Coughlin

Internal Medicine Augusta, GA Medical Doctor

NPI 1508832338 CMS profile 113896

2258 Wrightsboro Rd Ste 300, Augusta, GA 30904

Open in the dashboard

General payments

$14,631

982 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Renee Coughlin of Augusta, GA is reported in the CMS Open Payments database as having received $14,631 across 982 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53 3
2024 General $2,315 145
2023 General $3,007 196
2022 General $2,804 176
2021 General $2,366 165
2020 General $2,139 151
2019 General $1,947 146

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Renee Coughlin
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Renee Coughlin were reported at $53. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Renee Coughlin Internal Medicine median Middle half National median
2019 $1,947 $159 $48–$570 $163
2020 $2,139 $119 $33–$402 $114
2021 $2,366 $135 $37–$521 $132
2022 $2,804 $141 $42–$496 $149
2023 $3,007 $149 $45–$519 $160
2024 $2,315 $154 $47–$537 $164
2025 $53 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $2,556 193 payments
  2. AbbVie, Inc. $1,785 148 payments
  3. AstraZeneca Pharmaceuticals LP $1,533 80 payments
  4. Lilly USA, LLC $1,220 84 payments
  5. GlaxoSmithKline, LLC. $1,098 94 payments
  6. Sanofi-Aventis U.S. LLC $864 53 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $828 48 payments
  8. Pfizer Inc. $617 46 payments
  9. Novartis Pharmaceuticals Corporation $472 27 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $432 21 payments
  11. Other $3,226 188 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,587 980 payments
  2. Education $44 2 payments
Products named General payments · program years 2019–2025
  1. Ozempic $2,022 155 payments
  2. RYBELSUS $1,475 109 payments
  3. FARXIGA $1,255 66 payments
  4. TRELEGY ELLIPTA $826 69 payments
  5. MOUNJARO $720 46 payments
  6. UBRELVY $685 58 payments
  7. VRAYLAR $602 43 payments
  8. JARDIANCE $595 33 payments
  9. BREZTRI $476 11 payments
  10. Kerendia $432 21 payments
  11. Other $10,578 719 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 181 drugs

Part D claims

12,070

Median for Internal Medicine: 777

Drug cost

$986,032

Median for Internal Medicine: $73,373

Branded share of claims

22.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 104 $148,108
Mounjaro Tirzepatide Brand 102 $141,702
Eliquis Apixaban Brand 97 $96,987
Jardiance Empagliflozin Brand 90 $80,930
Januvia Sitagliptin Phosphate Brand 71 $75,489
Farxiga Dapagliflozin Propanediol Brand 59 $53,760
Linzess Linaclotide Brand 46 $38,205
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 37 $34,294
Myrbetriq Mirabegron Brand 41 $29,238
Xarelto Rivaroxaban Brand 13 $22,773

The 10 drugs with the highest cost, of 181 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 27 billing codes

Paid by Medicare

$50,737

Of which drugs: $3,387

Medicare patients

236

Average age 75

Services billed

857

184 women, 52 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 39%
Chronic kidney disease 33%
Ischemic heart disease 26%
Depression 22%
Heart failure 19%
COPD 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 30 30 $2,455

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
$240 102 —
RYBELSUS
$164 18 —
Ozempic
$164 104 —
UBRELVY
$152 — —
JARDIANCE
$131 90 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

982 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record